What is DRPLA?
Dentatorubral-pallidoluysian atrophy, commonly known as DRPLA, is a progressive brain disorder that affects coordination, balance, speech, and causes involuntary movements, emotional problems, and a decline in thinking ability. The average age of onset of DRPLA is 30 years, but this condition can appear anytime from infancy to adulthood. The symptoms and progression vary depending on the age of onset.
What is CureDRPLA?
CureDRPLA is a US based non-profit founded by Paul and Andrea Compton. Paul and Andrea have a son that was diagnosed with DRPLA in August 2018. The mission of CureDRPLA is to connect families, physicians and scientific investigators to further DRPLA research and work towards a treatment for DRPLA. This webpage was created to find others that have this condition and are interested in finding a cure.
CureDRPLA
Global
Patient
Registry
The CureDRPLA Global Patient Registry is a worldwide registry of DRPLA patients.
This registry gathers the demographic and clinical information on DRPLA patients from across the globe. By collecting information on all DRPLA patients, the CureDRPLA Global Patient Registry will be a powerful resource for research and will enhance opportunities for treatment development.
Patient & Caregiver
Click below to find out what CureDRPLA has done and what we are currently doing to find to a treatment for DRPLA. You will also find online resources and support organizations for DRPLA as well as YouTube channels specifically focused on DRPLA.
Click below to find out what CureDRPLA has done and what we are currently doing to find a treatment for DRPLA. You will also find online resources and support organizations for DRPLA as well as YouTube channels specifically focused on DRPLA.
Patient &
Caregiver
Researcher
& Industry
CureDRPLA is investing in a number of projects in hopes of rapidly developing novel therapeutics for DRPLA. Information on funding opportunities, a list of our preclinical projects as well as other efforts can be found here.
Latest
News
Paul Compton shares insights on DRPLA n-of-1 trial in n-Lorem’s podcast
CureDRPLA co-founders, Paul and Andrea Compton, have a son with DRPLA and their personal experiences with this devastating condition are the driving force behind CureDRPLA. Earlier this year, CureDRPLA announced that n-Lorem had an experimental treatment for DRPLA and...
Nissan Chemical and Sanwa Kagaku announce plans to develop drug for DRPLA
Nissan Chemical Corporation and Sanwa Kagaku Kenkyusho Co., Ltd., two Japanese companies, have announced they recently co-created an antisense oligonucleotide (ASO) for DRPLA. ASOs have emerged as a promising strategy for various neurodegenerative conditions,...
Group of volunteers organize booth at neurology conference in Tokyo
Junko Shiozawa, Advisory Board Member to CureDRPLA, has created a community of Japanese families affected by DRPLA. They offer peer support to each other and host online meetings. Since DRPLA is more common in Japan, it was important for us to create a Japanese...
Social
International Congress for Ataxia Research – ICAR 2026
ataxiacongress.org
International Congress for Ataxia Research 2026 Ataxias and Beyond: Shared Pathways, Shared ProgressAtlanta, GA | 10-13 November 2026 REGISTER FOR ICAR 2026 VIEW PROGRAM The 2026 International Congres...
Nano-rare Patient Colloquium 2026 – Agenda
www.nlorem.org
[fusion_builder_container type=flex hundred_percent=no hundred_percent_height=no min_height_medium= min_height_small= min_height= hundred_percent_height_scroll=no align_content=stretch flex_align_item...
All About Ataxia November 2026 - Ataxia UK
www.ataxia.org.uk
Join us at our next All About Ataxia seminar on Thursday the 26th of November 2026. We have redesigned the format of All About Ataxia to enable it to be a one day online event, 10am-2pm. We ask that y...
Oxford-Harrington Rare Disease Centre Symposium 2026 - CureDRPLA
curedrpla.org
Dr Elisa Martelletti recently attended the Oxford-Harrington Rare Disease Centre Symposium, which brought together experts from academia, industry, healthcare, and patient advocacy to discuss advances...
CureDRPLA Global Patient Registry
The CureDRPLA Global Patient Registry aims to collect data on up to as many DRPLA patients as possible. Participants will be asked to complete a set of questionnaires after enrollment with email requests for yearly updates. Data collected include participant demographic and contact information, details about diagnosis, functional mobility status, health economics, medical history, and activities of daily living.